Democratic People's Republic of Korea national influenza programme: influenza factsheet 2019

Democratic People’s Republic of Korea Influenza Surveillance – Landscape Analysis 2019 INFLUENZA FACTSHEET 2019 DEMOCRATIC PEOPLE’S REPUBLIC OF KOREA National Influenza Programme Basic information (2019) Total population 25 448 3501 Children <5 years of age 1 634 7971 Under-5 mortality rate (per 1000 live births) 161 Life expectancy at birth (years) 74.12 Provinces/divisions/regions/zones 13 (9 provinces, 4 cities) Districts 209 Total health expenditure (% of GDP) 7.01 Income level (World Bank) Low3 1https://www.who.int/southeastasia/health-topics/immunization 2https://www.who.int/gho/publications/world_health_statistics/2020/en/ 3https://data.worldbank.org/ Influenza Like Illness (ILI) Surveillance Type of ILI surveillance Sentinel Sites involved in ILI surveillance Primary health centres Clinical case definition used for ILI case ascertainment WHO 2014 Is laboratory confirmation sought in ILI cases? Yes, (systematic ,1 in 10 enrolled subjects) Number of ILI surveillance sites 48 Number of states/districts covered by the surveillance system 9 provinces & 4 municipalities % of the population covered by the surveillance system 100 Denominator used for ILI surveillance Number of outpatient visits Reporting frequency to the national level Weekly How are the data reported? Aggregated data Form of the reporting tool Electronic Severe Acute Respiratory Infection (SARI) Surveillance Type of SARI surveillance Sentinel Sites involved in SARI surveillance Hospitals (inpatients) Clinical case definition used for SARI case ascertainment WHO 2014 Is laboratory confirmation sought in SARI cases? Yes, all enrolled subjects Number of SARI surveillance sites 68 Number of states/districts covered by the surveillance system 9 provinces & 4 municipalities % of the population covered by the surveillance system 100 Denominator used for SARI surveillance Number of inpatient visits Reporting frequency to the national level Weekly How are the data reported? Aggregated data Form of the reporting tool Electronic Influenza Surveillance – Landscape Analysis 2019 Democratic People’s Republic of Korea Intensive Care Unit (ICU) surveillance Does the country have surveillance for influenza in the ICU? Yes Is laboratory confirmation sought in ICU cases? - Is case-based information collected? Yes Mortality surveillance Is timely all-cause mortality data (i.e. within one month) available in the country? Yes Virological surveillance Does the country have virological surveillance? Yes Type of virological surveillance Sentinel – If sentinel, number of sites involved 116 Is epidemiological case information collected? Yes – If yes, are the laboratory results linked with epidemiological data? Yes Average number of virological samples processed per week 30 Are samples processed from ILI or SARI surveillance systems? Yes, both Does the country have virus isolation capacity? Yes Does the country have RT-PCR capacity? Yes – laboratories that perform RT-PCR - – RT-PCR laboratories that report to NIC - Does the country use rapid diagnostic testing for influenza surveillance? Yes – immunochromatography Does the country have sequencing capacity? No Does the country test for other respiratory viruses? Yes Virological data (FluNet) 0 10 20 30 40 50 60 0 50 100 150 200 250 300 350 1 5 9 14 18 23 27 31 36 40 45 49 1 5 9 14 18 23 27 31 36 40 45 49 1 5 9 14 18 23 27 31 36 40 45 49 2017 2018 2019 % po sit ive Nu mb er of po sit ive A/H1N1pm09 A/H1N1 A/H3N2 A/H5N1 A (Unsubtyped) B Yamagata Plotted in R (ggplot2). Data source: FluMART, available at http://apps.who.int/flumart/ Democratic People’s Republic of Korea Influenza Surveillance – Landscape Analysis 2019 National Influenza Centre Does the country have a National Influenza Centre (NIC) or national laboratory? Yes, NIC (established in 2009) Assays routinely performed at the NIC or national laboratory PCR Does the NIC have – Virus isolation capability – Antigenic characterisation capability – Antiviral susceptibility testing capability – Sequencing capability Yes Yes Yes No Does the NIC test for other respiratory viruses? Yes – Respiratory Syncytial Virus Does the country have a quality control plan? Yes Does the country follow national biosafety and biosecurity policy guidelines? Yes Does the country forward samples to a WHO Collaborating Centre (CC)? No – How often? N/A Reporting Frequency of national reports Every two months Are epidemiological and virological data integrated? Yes, both epidemiological and virological data Reported via a website? No Does the country report to FluID? – Year of beginning of reporting – Frequency of reporting Yes 2018 Monthly Does the country report to FluNet? – Year of beginning of reporting – Frequency of reporting Yes 2019 Monthly Are there fixed outbreak thresholds? Yes Level at which data are stored, managed and analysed National and provincial Has formal training on data reporting and analysis been provided to surveillance and laboratory staff? – If yes, when? – Has a training session been planned? If yes, when? Yes 2019 Yes, 2020 Vaccination Does the country have a formal seasonal influenza vaccination policy? No Has seasonal influenza been introduced in the public sector? – Year introduced – Recommended risk groups – Vaccination period – Northern/Southern hemisphere vaccine ? – Vaccine type No - - - - - Is seasonal influenza offered in the private sector? – Only offered to particular risk groups? – Vaccination period – Northern/Southern hemisphere vaccine ? – Vaccine type No - - - - Is vaccine offered to Hajj and Umrah pilgrims? No Vaccine production capacity No Influenza Surveillance – Landscape Analysis 2019 Democratic People’s Republic of Korea For technical information, please contact: Dr Pushpa Ranjan Wijesinghe, Programme Area Manager (Infectious Hazard Management). Email: wijesinghep@who.int Pandemic preparedness Does the country have a National Influenza Pandemic Preparedness Plan? – Year developed – Year last updated Yes 2009 Planned for 2020 Has the country performed simulation exercises? Yes Are there laboratory testing strategies in place for different phases of an influenza pandemic? Yes Are there surge capacity plans? Yes, included in the NIPPP Does the pandemic preparedness plan include a detailed National Pandemic Vaccine Deployment Plan? – Are there priority groups? No No